01 Advances in our knowledge of the molecular characteristics of HCC, combined with the development of new liquid biopsy technologies, have enabled significant progress in the early detection and therapeutic monitoring of HCC using blood. Liquid biopsy is a non-invasive alternative to tissue biopsy and provides information about tumor characteristics through assays of body fluids.
02 Liquid biopsy has advantages over traditional tissue biopsy: sample collection is minimally invasive, and liquid biopsy also allows repeated sampling, thereby enabling real-time monitoring of the patient’s molecular characteristics. In addition, unlike tissue biopsy, which is affected by intratumor heterogeneity, liquid biopsy can provide a heterogeneous molecular profile.
03 Liquid biopsy is more accessible to patients, so it facilitates routine checks-ups and recurrence monitoring. Liquid biopsy also enables personalized diagnosis for individual patients
Liquid biopsy can assess circulating tumor cells, circulating tumor DNA (ctDNA), and cell-free DNA. LepiDyne determines methylation levels in circulating tumor DNA and cell-free DNA.
Our product focuses on cancer screening and treatment monitoring using the amount of ctDNA and the methylation levels of DNA biomarkers.